Finally, a phase I clinical trial (NCT04111458; https://clinicaltrials.gov/ct2/show/NCT04111458 (accessed on 20 June 2021); Table 1) has also recently been started with BI-1701963 (a compound which exhibits high similarities in its mode of action with BI-3406) [46] that is focused on patients with advanced KRAS-mutated cancers, in order to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic properties (Table 1). This evidence concerns the gene KRAS and cancer.